allosteric inhibitors

allosteric inhibitors

substances which prevent an enzyme from changing into an active form by combining not with the ACTIVE SITE but with some other part of the enzyme.
References in periodicals archive ?
sup][17] Up-to-date, lots of IKK[sz] inhibitors have been developed including ATP analogs (PS-1145 and ML120B), allosteric inhibitors (BMS-345541), and thiol-reactive compounds (parthenolide and arsenite).
to cover many current and relevant aspects of protein-protein interactions, overcoming resistance in drug design, and allosteric inhibitors.
Instead, this new class, called allosteric inhibitors, changes the shape of the target enzyme and in doing so, renders it inactive.
The reversible Hill equation is widely used to model the kinetics of biochemical reaction networks with allosteric inhibitors and/or activators.
Understanding the issues that govern HIV-PR flap mobility has profound implications for elucidating the detailed mechanism of this enzyme and in the design of new therapeutic agents, such as allosteric inhibitors intended to interfere with flap opening and, thereby, with protease function.
Company successfully discovered and optimized the first small molecule allosteric inhibitors of ACC achieving excellent potency, selectivity and drug-like properties within 12 months -
Abstract #371: Cell based replicon validation of novel HCV NS3 allosteric inhibitors result in a new therapeutic approach
The discovery of allosteric inhibitors of MEK kinase
The Company identified small molecule allosteric inhibitors of the Aurora/Centrosome pathway and identified the target in the pathway as the Polo-Like Kinase 3 (PLK3) protein.
The p38 portfolio is comprised of highly selective allosteric inhibitors of p38 alpha and beta isozymes and LP-590, a multikinase inhibitor of p38, Tie-2, and Ret kinases.
We are excited about recent progress in our Aurora/Centrosome inhibitor program where we identified small molecule allosteric inhibitors of the PLK3 protein.
The Aurora/Centrosome pathway is important in many cancers; therefore, we believe that the identification of these allosteric inhibitors of the PLK3 protein is a significant advancement in the development of potential therapeutics for cancer," said Dr.